VIRGINIA RETIREMENT SYSTEMS ET Al Acquires Shares of 92,218 IDEXX Laboratories, Inc. $IDXX

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 92,218 shares of the company’s stock, valued at approximately $48,547,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned about 0.12% of IDEXX Laboratories at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the stock. SHP Wealth Management acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $26,000. Virtus Advisers LLC acquired a new position in IDEXX Laboratories during the 3rd quarter worth $26,000. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories in the 2nd quarter valued at $25,000. Elevation Wealth Partners LLC boosted its position in IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after buying an additional 32 shares during the last quarter. Finally, Wormser Freres Gestion increased its stake in shares of IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 47 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $535.38 on Monday. The firm has a fifty day moving average of $558.27 and a two-hundred day moving average of $570.05. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The stock has a market capitalization of $42.18 billion, a price-to-earnings ratio of 37.65, a PEG ratio of 2.86 and a beta of 1.54. IDEXX Laboratories, Inc. has a 52 week low of $518.55 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of recent research reports. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Citigroup raised their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Barclays dropped their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Finally, UBS Group upped their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.